Publications

Journal Article
Review Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't
Ppublish 53 citations
Electronic publication date
March 4, 2023

View on Pubmed.gov 36070840 | View on doi.org 10.1016/j.trsl....

Inflammasome activation in traumatic brain injury and Alzheimer's disease.

Search for publications in this journal Transl Res

Abstract

Traumatic brain injury (TBI) and Alzheimer's disease (AD) represent 2 of the largest sources of death and disability in the United States. Recent studies have identified TBI as a potential risk factor for AD development, and numerous reports have shown that TBI is linked with AD associated protein expression during the acute phase of injury, suggesting an interplay between the 2 pathologies. The inflammasome is a multi-protein complex that plays a role in both TBI and AD pathologies, and is characterized by inflammatory cytokine release and pyroptotic cell death. Products of inflammasome signaling pathways activate microglia and astrocytes, which attempt to resolve pathological inflammation caused by inflammatory cytokine release and phagocytosis of cellular debris. Although the initial phase of the inflammatory response in the nervous system is beneficial, recent evidence has emerged that the heightened inflammatory response after trauma is self-perpetuating and results in additional damage in the central nervous system. Inflammasome-induced cytokines and inflammasome signaling proteins released from activated microglia interact with AD associated proteins and exacerbate AD pathological progression and cellular damage. Additionally, multiple genetic mutations associated with AD development alter microglia inflammatory activity, increasing and perpetuating inflammatory cell damage. In this review, we discuss the pathologies of TBI and AD and how they are impacted by and potentially interact through inflammasome activity and signaling proteins. We discuss current clinical trials that target the inflammasome to reduce heightened inflammation associated with these disorders.

References

Cell Stress. 2018 Jun 29;2(7):150-161

J Neurosci. 2011 Jun 29;31(26):9513-25

Neurocrit Care. 2022 Apr;36(2):527-535

J Cereb Blood Flow Metab. 2009 Jul;29(7):1251-61

Cited by 53 citations (total)

Review Journal Article

Research progress of neuroinflammation-related cells in traumatic brain injury: A review.

Electronic publication date June 26, 2023

Search for publications in this journal Medicine (Baltimore)

Qinghui Zhao [...] Jianhua Zhang et al.

Neuroinflammation after traumatic brain injury (TBI) is related to chronic neurodegenerative diseases and is one of the causes of acute...

Journal Article Review

An Expanded Narrative Review of Neurotransmitters on Alzheimer's Disease: The Role of Therapeutic Interventions on Neurotransmission.

Electronic publication date January 27, 2025

Search for publications in this journal Mol Neurobiol

Enes Akyuz [...] Mohd Farooq Shaikh et al.

Alzheimer's disease (AD) is a progressive neurodegenerative disease. The accumulation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles are the...

Conflict of interest statement

Conflicts of Interest JPdRV, HMB, RWK, and WDD are co-founders and managing members of InflamaCORE, LLC and have licensed patents on inflammasome proteins as biomarkers of injury and disease as well as on targeting inflammasome proteins for therapeutic purposes. JPdRV, HMB, RWK, and WDD are Scientific Advisory Board Members of ZyVersa Therapeutics. NHJ declares no conflicts of interest.

MeSH

Specialties

Substances

Copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.